• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Blood Medicine >Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
【24h】

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia

机译：评价依鲁替尼治疗有症状的沃尔登斯特罗姆巨球蛋白血症

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Waldenstrom’s macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma with indolent course and prolonged disease course. The first-in-class Bruton’s tyrosine kinase inhibitor, ibrutinib, has shown significant activity and a distinct adverse event profile among both newly diagnosed and relapsed/refractory WM patients. Interestingly, clinical responses to ibrutinib have been shown to be dependent on patients’ MYD88 and CXCR4 mutational status. The recent outcomes of the Phase III iNNOVATE trial showed that the combination of ibrutinib with rituximab resulted in a significantly prolonged progression-free survival compared with rituximab monotherapy, which provides a novel therapeutic option in the clinical practice especially for the rituximab-refractory WM patients. However, the need for continuous drug administration along with the unique toxicity manifestations may render the patient management challenging. Furthermore, our understanding of the underlying resistant mechanisms to ibrutinib is currently being evolved.
机译：Waldenstrom的巨球蛋白血症（WM）是一种罕见的淋巴浆细胞性淋巴瘤，病程缓慢，病程延长。一流的布鲁顿酪氨酸激酶抑制剂依鲁替尼在新诊断和复发/难治性WM患者中均表现出显着的活性和明显的不良事件。有趣的是，已证明对依鲁替尼的临床反应取决于患者的MYD88和CXCR4突变状态。 iNNOVATE III期试验的最新结果表明，与利妥昔单抗单药治疗相比，依鲁替尼与利妥昔单抗联合使用可显着延长无进展生存期，这在临床实践中尤其是对利妥昔单抗难治性WM患者提供了一种新的治疗选择。然而，对连续给药以及独特的毒性表现的需求可能使患者管理具有挑战性。此外，我们对依鲁替尼潜在耐药机制的了解目前正在发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号